Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Topical IDP-118 in Plaque Psoriasis
NCT01670513Phase 2Unknown
- Sponsor
- Dow Pharmaceutical Sciences
- Start
- Jun 2012
- Primary completion
- May 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of halobetasol propionate + tazarotene in plaque psoriasis, sponsored by Dow Pharmaceutical Sciences. Status: unknown.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01670513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670513.